Primary Liver Cancer (PLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Primary Liver Cancer (PLC) Market Outlook

Thelansis’s “Primary Liver Cancer (PLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Liver Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Liver Cancer Overview

Primary liver cancer (PLC) is a malignant disease with significant histological and biological diversity. The clinical manifestations of liver cancer are often nonspecific and not evident until cancer has progressed to an advanced stage. These symptoms may comprise unexplained weight loss, loss of appetite, postprandial fullness, nausea, vomiting, abdominal pain or swelling, jaundice (yellowing of the skin and sclera), pruritus (itchy skin), and fatigue. Primary liver cancer is mainly divided into hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and HCC-ICC according to pathological type. Each subtype exhibits a distinct genetic makeup and molecular patterns. HCCs are associated with genetic alterations in specific chromosomal regions and genes, including TERT promoter mutation, TP53 deletion, and activation of WNT signaling (CTNNB1 and AXIN1). ICCs exhibit a unique mutational landscape with recurrent mutations, including genetic alterations in TP53, KRAS, isocitrate dehydrogenase (IDH) 1/2, and fibroblast growth factor receptor (FGFR) gene fusions. Combined cHCC-ICCs show ICC-like features, while mixed cHCC-ICCs exhibit HCC-like features. The prognosis of liver cancer is affected by many factors, including tumor factors, the patient’s general state of health, and liver function. Therefore, several staging systems exist, such as the BCLC, TNM, JSH, and APASL staging systems.

• In the USA, Primary liver cancer has shown an incidence of 3.3 per 100,000 annually. 

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: